Conclusion: VEGFR-2 −906 C>T, CXCR-2 +1208 C>T and PAR-1 −506 Ins/Del polymorphisms are potential predictors for survival in PC. Key words: CXCR-2, PAR-1, pancreatic cancer, polymorphism, tumor angiogenesis, VEGFR-2 introduction Individualization of diagnostics and therapy in patients with malignant disease is believed to be the next crucial step in cancer therapy and extensive efforts are being made to identify potential prognostic markers in several tumor entities. Established clinical useful markers to stratify patients with pancreatic cancer (PC) to different risk groups and refine patients who would benefit from adjuvant chemotherapy are missing. Several studies underline the impact of genomic variations on disease development and course. Genomic variations reflected by germline polymorphisms may represent promising prognostic markers because they are stable, easily accessible and unbiased by genomic instability occurring in cancer tissue [1] .
An increasing interest exists on genetic variations influencing tumor angiogenesis and the hypoxic environment of PC implicates high vascular ingrowth, which may be influenced by angiogenesis-related germline polymorphisms. Angiogenesis is dependent on complex interactions of various pro-and antiangiogenic molecules, and the vascular endothelial growth factor (VEGF) pathway plays a pivotal role. VEGF promotes vascular endothelial cell survival, proliferation, migration and vascular permeability mainly over the vascular endothelial growth factor receptor 2 (kinase insert domain receptor, VEGFR-2). Overexpression of VEGF is associated with tumor progression and prognosis in several tumor entities [2] [3] [4] . Additionally, platelets containing endostatin (collagen type XVIII alpha 1, ES) and VEGF are believed to influence tumor angiogenesis and the release of VEGF, and ES is mediated through proteinaseactivated receptor 1 (coagulation factor II thrombin receptor, PAR-1) located on platelets [5] [6] [7] . Besides, interleukin-8 (IL-8) induces tumor angiogenesis, independent of VEGF pathway, through chemokine the CXC motif receptor 2 (CXCR-2) [8] . Our purpose was to evaluate germline polymorphisms of VEGFR-2, CXCR-2, PAR-1 and ES as prognostic markers for disease-free survival (DFS) and overall survival (OS) in PC.
materials and methods samples
This study was approved by the Ethics Committee of the chamber of physicians, Hamburg, Germany. Informed consent was obtained from all patients before including them in a prospective database. The study is in concordance with the 'Reporting recommendations for tumor marker prognostic studies' [9] . In total, 173 Caucasian patients who had been diagnosed and surgically treated for PC between 2004 and 2011 were included in this study. Clinicopathological data were extracted from a prospective database. Follow-up data were obtained by interviews with the attending physician or the patient himself. None of the patients had received neoadjuvant treatment.
polymorphisms
In total, nine angiogenesis-related polymorphisms were selected for genotyping of PC samples (VEGFR-2 +1416 T>A, rs1870377, VEGFR-2 −92 G>A, rs1531289; VEGFR-2 −271 G>A, rs7667298; VEGFR-2 −906 C>T, rs2071559; CXCR-2 +1208 C>T, rs1126579; CXCR-2 +785 C>T, rs2230054; PAR-1 −506 Ins/Del, rs11267092, PAR-1 −14 Ivs A>T, rs168753 and ES +4349 G>A, rs12483377).
The selection of these specific polymorphisms was based on the following criteria:
• They had to be well documented and established.
• A probable functional impact based on preceded publications had to exist.
• A minor homozygous allele frequency of at least 5% published for Caucasian populations at National Center for Biotechnology Information Databank (http://www.ncbi.nlm.nih.gov/snp) was required.
DNA extraction, sequencing and genotyping
Peripheral blood leukocyte DNA was extracted and purified accordant to the manufacturer protocol using a QIAamp tissue kit (Qiagen, Hilden, Germany). DNA concentration was determined via NanoDrop® (Wilmington, DE) ND-1000 Spectrophotometer and samples were diluted to 10 ng/µl. SNP genotyping was carried out accordant to the TaqMan® genotyping protocol (Applied Biosystems, Carlsbad, CA) with 20-ng DNA template. Except for rs11267092 all SNP's were genotyped by existing and established TaqMan® genotyping assays. Each run had a positive control for homozygous genotypes, which had been verified by sequencing.
PAR Concerning survival analysis, 37 patients for DFS and 32 for OS were excluded due to macroscopic positive resection margins (R2), in-hospital mortality or loss to follow-up. UICC tumor stage showed a highly significant correlation with DSF (P = 0.003) and OS (P = 0.001). The majority of the study population included in survival analyses received gemcitabinebased adjuvant chemotherapy (77.4%). Postoperative chemotherapy as well as microscopic positive resection margins (R1) did not reveal a significant impact on clinical outcome (Table 1) .
polymorphisms
Allele frequencies were in concordance to published frequencies at the National Center for Biotechnology Information Databank (http://www.ncbi.nlm.nih.gov).
Homozygous and heterozygous at risk genotypes were combined together in a dominant model in case of frequency ≤10% for statistical analysis (VEGFR-2 +1416 T>A, VEGFR-2 −92 G>A, PAR-1 −506 Ins/Del, PAR-1 −14 Ivs A>T and ES +4349 G>A) and CXCR-2 +785 C>T was excluded from analyses due to a heterozygous genotype frequency of >95% in our cohort.
Correlations with histopathological characteristics, including tumor size, nodal status and grading or between the polymorphisms in 173 patients with PC were not evident.
The VEGFR-2 −906 C>T polymorphism had a significant impact on DFS (T/T versus C/T genotype: P = 0.016) and OS (T/T versus C/T: P = 0.026 and T/T versus C/C: P = 0.045, Table 2 ). Adjusted proportional multivariate analysis identified the −906 SNP as an independent prognostic marker for DFS (T/T versus C/T: P = 0.003, HR 2.2) and OS (T/T versus C/T: P = 0.011, HR 2.4; T/T versus C/C: P = 0.011, HR 2.4, Table 3 , Figure 1 ). Both, VEGFR-2 −271 G>A and −92 G>A polymorphisms indicated a borderline significant correlation with OS (VEGFR-2 −271 G>A: A/A genotype with 25.5 months versus A/G genotype with 16.5 months, P = 0.06 and Table 2) . VEGFR-2 +1416 T>A, did not show significant correlations in survival plots ( Table 2 ). The CXCR-2 +1208 C>T polymorphism showed significant correlations with DSF (T/T versus CT genotype: P = 0.003 and T/T versus C/C: P = 0.003) and was an independent prognostic marker for DFS (T/T versus C/T: P = 0.001, HR 0.4; T/T versus C/C: P < 0.0001, HR 0.4; Tables 2 and 3, Figure 1 ). In regard to OS a tendency towards shorter OS for patients with the T/T genotype was evident, but did not reach statistical significance (T/T genotype with 13.5 months versus C/C genotype with 21.1 months, P = 0.14, Table 2 ).
Patients with a homozygous genotype for deletion at position −506 of PAR-1 had a significant longer median DFS (Del/Del with 16.4 months versus Del/Ins or Ins/Ins with 10.3 months, P = 0.026) and showed a tendency toward longer OS (20.9 months versus 14.6 months, P = 0.10, Table 2 ). In multivariate analysis, the Del/Del genotype was identified as a positive predictor for DFS (Del/Del as reference versus Del/Ins or Ins/Ins, HR 1.7, P = 0.014, Table 3, Figure 1 ).
We carried out two models of multivariate analysis for OS in order to take account of potential confounding effects of other variables. The first model includes only significant polymorphisms identified in the univariate analysis (VEGFR-2 −906 C>T). The second model further includes polymorphisms that were identified as significant in multivariate analysis for DSF (VEGFR-2 −906 C>T, CXCR-2 +1208 C>T and PAR-1 −506 Ins/Del). The CXCR-2 +1208T/T genotype was an additional independent predictor for OS in model 2 (T/T versus C/T: P = 0.049, HR 0.6; T/T versus C/C: P 0.035, HR 0.5, Table 3 ). PAR-1 −14 Ivs A>T and ES +4349 (Table 2) . Combined multivariate analysis of positive prognostic markers for DFS (T/T genotype of VEGFR-2 −906, the C/T or C/C genotype of CXCR-2 +1208 and the Del/Del genotype of PAR-1) showed, that patients with ≤1 favorable genotypes were at the highest risk to develop relapse with a HR 4.8 and P < 0.0001. Patients with two favorable genotypes represented an intermediate risk group with HR 2.5 and P = 0.019, Table 3 , Figure 2 ).
In accordance to the results of the second model of multivariate analysis for OS, we carried out a combined multivariate analysis of positive prognostic markers for OS (T/T genotype of VEGFR-2 −906 and C/T or C/C genotype of CXCR-2 +1208). In concordance to the results of DFS, patients lacking favorable genotypes had the highest HR (0 versus 2 favorable genotypes: HR 4.8, P = 0.001; 0 versus 1 favorable genotype: HR 2.7, P = 0.006, Table 3, Figure 2 ). discussion Angiogenesis promotes disease progression and metastasis in several malignancies and is dependent on complex interactions of various pro-and antiangiogenic molecules and several clinical trials evaluate the combination of gemcitabine with antiangiogenic agents in PC [10] .
The VEGF pathway promotes survival, proliferation, migration and vascular permeability mainly through VEGFR-2 on vascular endothelial cells [3, 4, 11] . Our data implicates that the VEGFR-2 −906 C>T polymorphism seems to have a substantive impact on clinical outcome as a predictor for tumor recurrence and survival in PC. Homozygous T-allele carriers have significantly longer DFS and OS in comparison to heterozygous C-allele or homozygous C-allele carriers. Our results are in concordance to previous studies. The impact of VEGFR-2 −906 C/C genotype on tumor angiogenesis was described in colorectal cancer. Hansen et al. [12] verified a strong correlation between higher mean microvessel densities of C/ C genotype carriers in contrast to nonhomozygous C-allele carriers. Accordingly, the VEGFR-2 −906 C/C genotype was associated with poorer OS in patients with colorectal cancer. These findings are also in concordance with reported higher serum VEGFR-2 levels. Furthermore, the −906C variant introduces the binding site of the transcription factor IKZF2 and increases reporter gene expressions in human umbilical vein endothelial cells [13] . Recently, Glubb et al. [14] also reported a higher expression of the corresponding mRNA among −906C variant in nonsmall-cell lung cancer (NSCLC). Surprisingly, in regard to VEGFR-2 −906 C>T polymorphism, homozygous and heterozygous C-allele carriers had a comparable DFS in our study cohort, and the HR of C/T genotype was higher compared with the C/C genotype. Most likely, these results are due to our small study population. Reevaluation in a larger study cohort is therefore necessary in future studies. In regard to VEGFR-2 −271 G>A polymorphism, the reported divergent impact of VEGFR-2 −271 G>A polymorphism on mRNA and protein levels may have influenced the outcome of our results. Glubb et al. [13] were able to prove a correlation of VEGFR-2 −271 A/A genotype with lower VEGFR-2 protein levels in NSCLC. Accordingly, the VEGFR-2 −271 G/G genotype with anticipated higher VEGFR-2 protein levels had the shortest median OS. However, simultaneously, the −271 A/A genotype led to higher mRNA levels of VEGFR-2. The authors claimed, that low glucose conditions in the tumor microenvironment were responsible for glucose depletion, which in turn increases mRNA expression and down regulated VEGFR-2 protein levels [14] . However, these results are based on patients with NSCLC. The impact of this polymorphism on VEGFR-2 mRNA and protein stability in PC is not known so far.
The VEGFR-2 −92 G>A polymorphism is located in intron 25. Our results indicate tendency toward survival benefit for Aallele carriers in contrast to homozygous G-allele carriers. Kim et al. [15] reported an improved complete cytogenetic response of homozygous A-allele carriers following imatinib therapy. However, it is not clear how VEGFR-2 is involved in mechanisms of imatinib-based therapy. Kidd et al. [16] analyzed a Caucasian population of patients with breast cancer, and interestingly, A-allele carriers had a decreased DFS in univariate analysis. Additionally, a functional impact of −92 G>A on mRNA or protein levels of VEGFR-2 appears to be potentially relevant for tumor-related angiogenesis and further studies analyzing the biological relevance of this SNP may help to understand these divergent results.
Independent of VEGF pathway, IL-8 (a member of ELR(+) subgroup of CXC chemokines) promotes proliferation and survival of cancer cells and angiogenesis over CXCR-2, which is the central mediator of CXC chemokine-induced angiogenesis [8, 17] . The CXCR-2 +1208 C>T polymorphism showed significant correlations in PC with shortest median DFS of 9.0 months (T/T genotype) and was an independent negative predictor for DFS in multivariate analysis. Accordingly, addition of CXCR-2 antibodies to a corneal micropocket assay led to abrogation of CXC chemokineinduced angiogenesis. Furthermore, the expression of CXCR-2 is enhanced in PC and ELR+-CXC chemokines promote PCassociated angiogenesis through CXCR-2 [18, 19] . Consistent with our results, Snoussi et al. [20] demonstrated that CXCR-2 +1208 T allele is associated with a worse outcome in breast carcinoma, and Renzoni et al. [21] reported an increased frequency of CXCR-2 +1208 T/T and CXCR-2 +785 CC genotype in patients with systemic sclerosis, which is likewise an inflammatory-mediated disease. Comparable to VEGFR-2 SNP's, an influence on CXCR-2 mRNA levels or protein levels is assumed. However, up to now the functional impact of these polymorphisms is not proven.
Platelets containing angiogenesis inhibitors and stimulators (ES and VEGF) are believed to influence tumor angiogenesis additionally. Activation of PAR-1 by thrombin leads to platelet secretion and aggregation with influence on cell survival, apoptosis and angiogenesis [22, 23] . Ma et al. [6] were able to show that a selective PAR-1 agonist induced VEGF release and suppressed ES release, which leads to potential augmented activation of the VEGF pathway and plays a pivotal role in angiogenesis [5] . In our study cohort, patients homozygous for a 13-bp (5 0 -CGGCCGCGGGAAG-3 0 ) deletion within the promotor at position −506 of PAR-1 had an improved DFS compared with heterozygous or homozygous patients with insertion at −506. Accordingly, presence of insertion allele was a negative predictor for DFS in multivariate analysis. Similar results have been reported for populations with gastric and esophagus adenocarcinoma [24, 25] . Although verification of functional impact is pending, a conclusive explanation has been stated. The 13-bp sequence contains a recognition motif for activating erythroblastosis virus protein (ETS), which plays a major role in the formation of the transcriptional initiation complex in genes lacking the canonical TATA box sequence, similar to PAR-1 gene promoter. Lack of ETS recognition sequence may have a negative impact on PAR-1 transcription, which affects the PAR-1-mediated VEGF release of platelets, as postulated by Lurje et al. [24, 26, 27] .
Our results of the PAR-1 −14 Ivs A>T polymorphism did not show a significant difference between A-allele carriers and T-allele carriers. Although Dupont et al. [28] were able to prove that the density of PAR-1 on platelets is dependent on the −14 Ivs A>T polymorphism (A-T transversion in the intervening sequence), with a significant lower expression level of PAR-1 in presence of a T allele, we have to conclude that it has no impact on survival in PC [28] . Endostatin is a potent antiangiogenic growth factor and the A allele of +4349 G>A polymorphism was shown to be potentially responsible for impaired antiangiogenic function of endostatin [5, 7, 29] . Analogical to PAR 1 −14 Ivs A>T comparison of median DFS and OS did not point to a relevant impact of the A allele in PC.
The evaluation of polymorphisms as independent prognostic factors for survival was based on multivariate analysis stratified by age, gender and tumor stage. In our study cohort, the R1 resection rate was 36.0% (n = 49, DSF study cohort), respectively, 34.8% (n = 49, OS study cohort). Similar to the results of a published meta-analysis, we were not able to show a significant survival benefit for patients with R0 in univariate analysis [30] . Multivariate analysis additionally stratified by margin involvement (R0 versus R1) did not change our results (data not shown). Verbeke et al. [31] reported a clearly higher R1 rate (82%) using the Leeds Pathology Protocol. A bias caused by underreporting of microscopic margin involvement is potentially affecting our survival analysis. To eliminate a bias caused by application of adjuvant chemotherapy, we carried out a subgroup analysis including only patients that received adjuvant chemotherapy (n = 105). Results of multivariate analysis were similar to results obtained in the whole study population (data not shown).
In summary VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms may represent stable, easily accessible prognostic markers for PC. We identified three polymorphisms as predictors for DFS and two polymorphisms for OS in two independent angiogenesis activating pathways: VEGFR-2 −906 C>T and PAR-1 −506 Ins/Del in VEGF-mediated angiogenesis pathway and CXCR-2 +1208 C>T in CXC chemokinemediated angiogenesis pathway. Combined multivariate analysis for DFS and OS indicate that these polymorphisms enhance their effect on tumor angiogenesis if they are simultaneously present. Genotyping may therefore help to identify high-risk subgroups with potential benefit for patients suffering from PC.
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